Introduction {#s1}
============

Glucocorticoids (GC) are widely prescribed for the treatment of autoimmune and malignant diseases and can cause a dose-dependent increase in blood glucose levels in patients without adrenal insufficiency (AI) or pre-existing diabetes mellitus (DM) ([@r1]). The odds ratio for new-onset DM in patients treated with GC reportedly ranges from approximately 1.5 to 2.5 (1). GC-induced DM is theoretically less likely to occur in AI patients if adequate physiological replacement doses are given.

Herein we report the occurrence of GC-induced DM in a patient with holoprosencephaly (HPE). DM developed at least partly due to frequent and prolonged administration of high-dose GC for adrenal crisis (AC), referred to as acute AI in this manuscript. In this report, we highlight the importance of adjusting the initial and subsequent doses in order to avoid GC-induced DM.

Case Presentation {#s2}
=================

The patient was a 10-yr-old male child with intrauterine growth retardation born at 36 wk of gestation after a C-section due to fetal asphyxia (birth weight 1324 g). HPE was diagnosed according to the characteristic physical findings, including a cleft lip palate, microphthalmia, and diagnostic MRI findings. At the age of 2 yr, IGF-1, LH, FSH, TSH, and free T4 were 25.5 ng/mL, \< 0.07 mIU/mL, 1.14 mIU/mL, 3.94 μIU/mL, and 1.10 ng/dL, respectively. The patient did not have any symptoms of hypothalamic dysfunction, such as an instability of body temperature. The patient's obesity, shown in [Table 1](#tbl_001){ref-type="table"}Table 1.Case presentation, was probably due to excess calories. There was no replacement of hormonal agents other than hydrocortisone (HDC) up to the age of 10 yr and 9 mo.

AI was suspected based on a low basal cortisol level early in the morning (3.5 μg/dL) and a low cortisol level at the time of the AC (11.2 μg/dL) at 6 yr and 3 mo of age. A CRH loading test showed an equivocal peak cortisol level of 17.8 μg/dL (reference value, \> 18.0 μg/dL) at the time. Thus, administration of HDC (100 mg/m^2^/d) was started at 6 yr and 5 mo of age only in clinical situations in which AC was suspected. AI was not definitively diagnosed at this point. The patient was always bedridden, and his nutrition was provided entirely via tube feeding. He was unable to express his intentions or speak. Only objective findings, such as fever, tachycardia, and vomiting were clues to the possibility of AC.

There was no family history of DM. Risk factors for DM in this patient were obesity and lack of exercise. Prior to HDC therapy, which was initially done only when AC was suspected, random samplings of blood glucose yielded findings of 100 to 130 mg/dL. Transient postprandial hyperglycemia (368 mg/dL) was first recognized during a respiratory infection at 6 yr and 7 mo of age. The total amount of HDC was 1278.7 mg/m^2^ until then, and the total duration of HDC administration exceeding 8 mg/m^2^/d was 18 d ([Table 1](#tbl_001){ref-type="table"}). The highest dose (100 mg/m^2^/d) was administered for 16 of the 18 d. The episodes associated with suspected AC at that time were vomiting and respiratory infection, and the continuous administration of the highest dose during these episodes was 5 and 11 d, respectively. In retrospect, these durations were relatively long. Hyperglycemia in these periods resolved after discontinuation of HDC.

The total amount of HDC administered from 6 yr and 7 mo to 8 yr and 7 mo of age was 12036.3 mg/m^2^, and the total duration of administration exceeding 8 mg/m^2^/d was 224 d. The highest dose (100 mg/m^2^/d) was administered for 67 of the 224 d. The episodes associated with suspected AC were vomiting (7 episodes), respiratory infection (5 episodes), and tachycardia (1 episode), and the continuous duration of administration of the highest dose for these episodes was 2--8 d, 3--10 d, and 4 d, respectively. Postprandial hyperglycemia remained above 200 mg/dL after the age of 8 yr and 7 mo. The anti-GAD and -IA2 antibodies were negative at the time. GC-induced DM was diagnosed based on the HbA1c value (7.5%). As blood glucose occasionally declined naturally to around 140 to 160 mg/dL before tube feeding, the endogenous secretion of insulin apparently still continued although at low levels. Indeed, the IRI level was 12.4 mIU/mL when the blood glucose level was 180 mg/dL. Since the patient was obese, metformin (125 mg/d) was first introduced to improve insulin resistance but had no effect. Thus, insulin injections with insulin aspart and glargine were started at 8 yr and 9 mo old. The HbA1c at this time was 8.0%.

At 8 yr and 6 mo of age, the basal cortisol level early in the morning was undetectable (\< 1.0 μg/dL). The test was done before 9 o'clock before oral HDC administration when he visited us in a poor condition, or stressful situation. This cortisol level was consistent with the complete suppression of endogenous GC, and daily oral replacement of HDC (8 mg/m^2^/d) was started. ACTH deficiency at 6 yr and 3 mo was not unequivocally documented as explained above. Thus, the low peak value of cortisol (\< 1.0 μg/dL) at 8 yr and 6 mo might simply have reflected the subsequent excess of exogenous GC.

All 15 episodes that were treated with HDC for suspected AC and/or prevention of AC are shown in [Table 2](#tbl_002){ref-type="table"}Table 2.Clinical manifestations of each adrenal crisis episode on admission. Hyponatremia (122 mEq/L, 128 mEq/L) was recognized in two of the 15 episodes, which were apparently the only episodes of severe AC in retrospect. The duration of treatment with 100 mg/m^2^/d of HDC ranged from two to 11 d for these 15 episodes. Because vomiting, one of the most frequent symptoms in this patient, improved with treatment, we concluded that the vomiting episodes were related to AC. Other diseases causing vomiting such as ileus or gastroenteritis were denied.

At 10 yr and 9 mo old, the total amount of insulin was 1.2--1.4 U/kg/d, and HbA1c (NGSP) was 6.1%. The dose and frequency of HDC therapy for AC were not reduced after 8 yr 9 mo, and the patient needed over 1 U/kg/d insulin for two years until the time of this writing, suggesting that the steroid diabetes had become irreversible. Mild fatty liver detected by an echograph was the only symptom or finding relevant to the excess exogenous GC besides obesity and hyperglycemia (data not shown).

Discussion {#s3}
==========

We described a case of GC-induced DM in a patient with HPE. DM developed after frequent and prolonged administration of high-dose GC for suspected AC.

The maximum dose of HDC used for AC in this report (100 mg/m^2^/d) was not excessive for major stress or severe AC when compared to previous recommendations. A previous report mentioned that 100--400 mg/d of HDC should be administered to adults in cases of major stress, including open abdominal surgery, severe trauma, childbirth, and frequent diarrhea/vomiting ([@r2]). The clinical practice guidelines of the Japan Endocrine Society (JES) ([@r3]) recommend a continuous infusion of 150 mg of HDC for 24 h and the administration of 100 mg of HDC on the next day for cases of major physical stress in adults. The Endocrine Society (ES) recommends that suspected AC in children should be treated with an immediate parental injection of 50 mg/m^2^ HDC followed by 50--100 mg/m^2^/d of HDC ([@r4]).

One reason for the development of diabetes mellitus in this patient was the unusually high frequency of treatment with 100 mg/m^2^/d of HDC. If we follow the definition of major stress or severe AC by Grossman *et al*. ([@r2]), only two of 15 episodes treated with 100 mg/m^2^/d of HDC in our study apparently qualify as severe AC. The dose for treating AC theoretically varies according to the stress level; therefore, a lower dose could have been selected ([@r2]).

Another cause of GC-induced DM in our case was prolonged administration of high dose GC. While the acute symptoms persisted for one to three days, the duration of treatment with 100 mg/m^2^/d of HDC ranged from two to 11 d in our case ([Table 2](#tbl_002){ref-type="table"}). The prolonged administration was due to the patient's condition as described. In retrospect, the physicians had just finished administering HDC treatment when AC was completely recovered in the patient. The cortisol levels in critically ill children reportedly rise only during the first 24 h ([@r5]). The plasma CRH, ACTH, cortisol, norepinephrine, and renin activities in patients undergoing neck surgery returned to the basal levels by the first postoperative day ([@r6]). Serum cortisol levels in individuals with normal adrenal function reach a peak at the time of tracheal extubation immediately after the end of surgery and normalize within 48 h. Two of the most recent studies ([@r1],[@r2],[@r3]) do not mention the duration of GC administration during stress, whereas the Japanese guidelines recommended tapering to a maintenance dose over a period of 1--4 wk after symptom improvement in children ([@r3]). We believe that a tapering period of 1--4 wk is too long based on the findings of the present and previous reports ([@r5], [@r6]).

Several studies have reported on diabetes mellitus in patients with ACTH deficiency. A previous report mentioned that 2% of adults having hypopituitarism with ACTH deficiency developed DM after daily treatment with 20 mg HDC ([@r7]). In another report, GC therapy in hypopituitarism adults with 26 mg HDC was shown to cause mild elevations in the circulating glucose and insulin level without inducing overt DM even in the presence of an acceptable plasma cortisol level ([@r8]). However, these doses of 20 and 26 mg HDC are pharmacological, compared to physiological secretion of cortisol, or 6--8 mg/m^2^. These data suggest that the incidence of DM may not be high if the dose is physiological.

In conclusion, the possible causes of GC-induced DM in our case were frequent and prolonged administration of high-dose GC. As AC is a life-threatening complication in patients with chronic AI, treatment should be started whenever AC cannot be ruled out. However, the initial and subsequent doses should be adjusted depending on the severity of AC and on the pace of clinical recovery with treatment, respectively.

We are indebted to Mr. James R. Valera for his assistance in editing this manuscript.
